Indication
Details coming soon
Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Improve glycemic control in adults with type 2 diabetes mellitus Age: Adult |
Dose: Subcutaneous – Initial: 0.75 mg Frequency: once weekly Note: Indicated as adjunct to diet and exercise. |
|
Indication: Improve glycemic control in adults with type 2 diabetes mellitus Age: Adult Condition: Additional glycemic control needed |
Dose: Subcutaneous – 1.5 mg Frequency: once weekly |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Type 2 diabetes mellitus Age: 10 years and older |
Dose: Subcutaneous injection – 0.75 mg Frequency: once weekly Note: maximum dose 1.5 mg once weekly |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment (any severity) |
Dose: - Note: No dosage adjustment required |
Administration
- Inject subcutaneously once weekly
- Rotate injection sites
Side Effect
- Nausea (12.4-21.1%)
- Increased amylase (20%)
- Increased lipase (14%)
- Diarrhea (7-12.6%)
- Abdominal pain (6.5-9.4%)
- Vomiting (5.6-9.3%)
- Decreased appetite (4.9-8.6%)
- Fatigue (4.2-5.6%)
- Dyspepsia (2.3-5.8%)
- Constipation (3.7-3.9%)
- Severe hypoglycemia with prandial insulin (2.7-3.4%)
- Flatulence (1.4-3.4%)
- Sinus tachycardia (2.8-3%)
- Abdominal distension (2.3-2.9%)
- Gastroesophageal reflux disease (1.7-2%)
- AV block (0.9-1.7%)
- Eructation (0.6-1.6%)
- Hypersensitivity
- sometimes severe (eg severe urticaria, systemic rash, facial edema, lip swelling)
- Injection-site
- reactions
- Pancreatitis
- Cholelithaisis and cholecystitis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Sulfonylureas, insulin
|
Increased risk of hypoglycaemia
|
|
Oral medications
|
May delay gastric emptying and reduce rate of absorption
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Medullary Thyroid Carcinoma History
|
Risk of tumor development
|
|
Multiple Endocrine Neoplasia Syndrome Type 2
|
Risk of tumor development
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store Dulaglutide in the refrigerator at 2°C to 8°C. Do not use Dulaglutide beyond the expiration date. If needed, each single-dose pen can be kept at room temperature, not to exceed 30°C for a total of 14 days. Do not freeze Dulaglutide.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.